Post-knowledge questions

Before watching the CDK4/6 inhibitors as adjuvant therapy in early breast cancer webinar, please take a moment to evaluate your current level of knowledge on the topic by participating in this short quiz.

First name

Surname

Email address

1. What is currently the only approved CDK4/6 inhibitor for treating early breast cancer?

A. Ribociclib

B. Abemaciclib

C. Palbociclib

D. Dalpiciclib

2. Approval of abemaciclib for use in people with high-risk HR+/HER2− early breast cancer was based on clinical trial data from which study?

A. NATALEE

B. OlympiA

C. PENELOPE-B

D. monarchE

3. What PARP inhibitor is recommended for people with early breast cancer, BRCA mutation and a high risk of recurrence?

A. Talazoparib

B. Rucaparib

C. Olaparib

D. Niraparib

4. What topics in CDK4/6 inhibitors for treating early breast cancer would you like to learn more about?

Diagnosis

Efficacy and safety data for emerging therapies

Later-line treatment approaches

Real-world evidence

Supportive care

Congress highlights

Did the event fulfil your expectations?

5 - Entirely

4 - Somewhat

3 - Neutral

2 - Not really

1 - Not at all

Was the information balanced and supported by evidence?

5 – Entirely

4 – Somewhat

3 – Neutral

2 – Not really

1 – Not at all

Was this event free from commercial bias? 

5 – Entirely

4 – Somewhat

3 – Neutral

2 – Not really

1 – Not at all

Was there adequate time for Q&A?

5 – Entirely

4 – Somewhat

3 – Neutral

2 – Not really

1 – Not at all

Will you implement what was presented  in your  clinical practice?

Yes

No

How useful was each session?

1. Advances with CDK4/6 inhibitors in the EBC treatment landscape

5 – Entirely

4 – Somewhat

3 – Neutral

2 – Not really

1 – Not at all

2. Exploring the safety and tolerability of CDK4/6 inhibitors in EBC

5 – Entirely

4 – Somewhat

3 – Neutral

2 – Not really

1 – Not at all

3. Panel discussion: Optimal use of CDK4/6 inhibitors in EBC

5 – Entirely

4 – Somewhat

3 – Neutral

2 – Not really

1 – Not at all

4. Choosing the right treatment for EBC at high risk of recurrence

5 – Entirely

4 – Somewhat

3 – Neutral

2 – Not really

1 – Not at all

5. Panel discussion: Choosing the right treatment for EBC at high risk of recurrence – implementing guideline recommendations

5 – Entirely

4 – Somewhat

3 – Neutral

2 – Not really

1 – Not at all

I am happy to be contacted at a future date to share how learnings from this event have affected my clinical practice

I agree